RobertALasserMD

PubMed

• Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-L...
  Cutler, A., Mattingly, G., Zhang, H., Rana, N., Brown, C., Miller, C., Kotecha, M., Forrestal, F., Doherty, J., Kornstein, S., Aaronson, S., Lasser, R., Levin, S.> ;The Journal of Clinical Psychiatry. 2023 Dec 27
• 4 citations
  Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
  Sagar V Parikh, Scott T Aaronson, Sanjay J Mathew, Gustavo Alva, Charles DeBattista, Stephen Kanes, Robert Lasser, Amy Bullock, Mona Kotecha, JungAh Jung, Fiona Forres...> ;Neuropsychopharmacology. 2024 Jan 1
• 22 citations
  Zuranolone for the Treatment of Postpartum Depression.
  Kristina M Deligiannidis, Samantha Meltzer-Brody, Bassem Maximos, E Quinn Peeper, Marlene Freeman, Robert Lasser, Amy Bullock, Mona Kotecha, Sigui Li, Fiona Forrestal,...> ;The American Journal of Psychiatry. 2023 Sep 1
• 20 citations
  Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
  Anita H Clayton, Robert Lasser, Indrani Nandy, Abdul J Sankoh, Jeffrey Jonas, Stephen J Kanes> ;The Journal of Clinical Psychiatry. 2023 Feb 20
• 10 citations
  Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
  Kristina M Deligiannidis, Leslie Citrome, Ming-Yi Huang, Sarah Acaster, Moshe Fridman, Vijayveer Bonthapally, Robert Lasser, Stephen J Kanes> ;The Journal of Clinical Psychiatry. 2023 Jan 30
• 19 citations
  Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-contr...
  C Neill Epperson, David R Rubinow, Samantha Meltzer-Brody, Kristina M Deligiannidis, Robert Riesenberg, Andrew D Krystal, Kemi Bankole, Ming-Yi Huang, Haihong Li, Colv...> ;Journal of Affective Disorders. 2023 Jan 1
• 12 citations
  Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
  Ellison Suthoff, Mark Kosinski, Alix Arnaud, Paul Hodgkins, Handan Gunduz-Bruce, Robert Lasser, Christopher Silber, Abdul J Sankoh, Haihong Li, Brian Werneburg, Jeffre...> ;Journal of Affective Disorders. 2022 Jul 1
• 88 citations
  Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
  Kristina M. Deligiannidis, Samantha Meltzer-Brody, H. Gunduz-Bruce, James J. Doherty, Jeffrey Jonas, Sigui Li, Abdul J. Sankoh, Christopher Silber, Andrew Campbell, Br...> ;JAMA Psychiatry. 2021 Sep 1
• Comment on "Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids".
  David R. Rubinow, Robert Lasser, Stephen J. Kanes> ;The American Journal of Psychiatry. 2021 Jun 1
• 7 citations
  ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years.
  Frank A. Lopez, Ann C. Childress, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner, Robert A. Lasser, John Shepski, Valerie Arnold> ;Journal of Attention Disorders. 2017 Jan 1
• 49 citations
  Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder
  Manisha Madhoo, Richard S.E. Keefe, Robert M. Roth, Angelo Sambunaris, James Wu, Madhukar H. Trivedi, Colleen Anderson, Robert Lasser> ;Neuropsychopharmacology. 2014 May 1
• 22 citations
  The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6 to 12 Years of Age With ADHD in a Double-Blind Placebo-Controlled Trial
  Ann C. Childress, Valerie Arnold, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner, Robert Lasser, Frank A. Lopez> ;Journal of Attention Disorders. 2014 Feb 1
• 37 citations
  A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Di...
  Madhukar H. Trivedi, Andrew J. Cutler, Cynthia Richards, Robert Lasser, Brooke Geibel, Joseph Gao, Angelo Sambunaris, Ashwin A. Patkar> ;The Journal of Clinical Psychiatry. 2013 Aug 15
• 48 citations
  Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a...
  Lenard A. Adler, Bryan Dirks, Patrick Deas, Aparna Raychaudhuri, Matthew Dauphin, Robert Lasser, Richard H. Weisler> ;The Journal of Clinical Psychiatry. 2013 Jul 15
• 37 citations
  Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.
  Robert Lasser, Bryan Dirks, Henry Nasrallah, Courtney Kirsch, Joseph Gao, Michael L. Pucci, Mary Ann Knesevich, Jean-Pierre Lindenmayer> ;Neuropsychopharmacology. 2013 May 8
• 4 citations
  Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use
  Rakesh K. Jain, Thomas Babcock, Teodor Burtea, Bryan Dirks, Ben Adeyi, Brian Scheckner, Robert Lasser, John Renna, Don Duncan> ;Advances in Therapy. 2013 May 17
• 5 citations
  Parent-Reported Executive Function Behaviors and Clinician Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms in Children Treated with Lisdexamfetamine Dimes...
  Robert L. Findling, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner, Robert Lasser, Anthony DeLeon, Lawrence D. Ginsberg> ;Journal of Child and Adolescent Psychopharmacology. 2013 Feb 14
• 28 citations
  Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder
  Greg Mattingly, Richard H. Weisler, Joel Young, Ben Adeyi, Bryan Dirks, Thomas Babcock, Robert Lasser, Brian Scheckner, David W. Goodman> ;BMC Psychiatry. 2013 Jan 29
• 10 citations
  Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylate.
  Alain Katic, Lawrence D. Ginsberg, Rakesh K. Jain, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner, Cynthia Richards, Robert Lasser, Atilla Turgay, Robert L. F...> ;Journal of Attention Disorders. 2012 Jul 1
• Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate.
  Mattingly G, Weisler R, Dirks B, Babcock T, Adeyi B, Scheckner B, Lasser R> ;Innov Clin Neurosci. 2012-05-01
• 99 citations
  Lifespan persistence of ADHD: the life transition model and its application.
  Atilla Turgay, David W. Goodman, Philip Asherson, Robert Lasser, Thomas Babcock, Michael L. Pucci, Russell A. Barkley> ;The Journal of Clinical Psychiatry. 2012 Jan 10
• 22 citations
  Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis.
  Rakesh K. Jain, Thomas Babcock, Teodor Burtea, Bryan Dirks, Ben Adeyi, Brian Scheckner, Robert Lasser> ;Child and Adolescent Psychiatry and Mental Health. 2011 Nov 4
• 15 citations
  Managing ADHD across the lifespan in the primary care setting.
  David W. Goodman, Robert Lasser, Thomas Babcock, Michael L. Pucci, Mary V. Solanto> ;Postgraduate Medicine. 2011 Sep 1
• 19 citations
  Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
  Lawrence Ginsberg, Alain Katic, Ben Adeyi, Bryan Dirks, Thomas Babcock, Robert Lasser, Brian Scheckner, Lenard A. Adler> ;Current Medical Research and Opinion. 2011 May 17
• 10 citations
  Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder.
  Scott H. Kollins, Sharon Youcha, Robert Lasser, Michael E Thase> ;Innovations in Clinical Neuroscience. 2011 Feb 1
• Join now to see all